Altre lingue Akeso, Inc.

Azioni

9926

KYG0146B1032

Biotecnologia

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:30 11/06/2026			Variaz. 5gg	Var. 1 gen.
87,80 ^HKD	-0,17%		-14,51%	-22,30%

06:48	Il CdA di Akeso approva un piano di riacquisto azioni da 200 milioni di HKD	MT
01/06	Akeso, Inc.: Nomura mantiene la raccomandazione Buy	ZM

Altre lingue

14:37	Akeso's Trustee, Senior Management to Buy Back Shares
06:48	Akeso Board Approves HK$200 Million Share Purchase Plan
08/06	Akeso, Inc.(SEHK:9926) added to Hang Seng China Enterprises Index
01/06	Summit drops as concerns over older patients cloud cancer trial data
01/06	Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
01/06	Summit Therapeutics Says Ivonescimab Improves Survival Over Tislelizumab in Phase III Lung Cancer Trial
31/05	HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
31/05	Akeso Announces Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in First-Line Sq-Nsclc in Harmoni-6 Phase Iii Study
31/05	Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31)
26/05	Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
18/05	Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
15/05	Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
15/05	Akeso Inc Announces Phase II Data of Ligufalimab Combination Therapy in Frontline Acute Myeloid Leukemia
28/04	Biodlink International Company Limited Announces Board and Board Committee Changes, Effective from 29 April 2026
28/04	Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
28/04	Akeso, Inc. Secures Multiple Authoritative Updates And Upgrades For Ivonescimab In The 2026 CSCO NSCLC Guideline
21/04	Akeso, Inc. Presents Positive Phase II Results For Cadonilimab Combination In Advanced Pancreatic Cancer
21/04	Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
07/04	Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
07/04	Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
31/03	Akeso, Inc. Announces the Results of Health-Related Quality of Life Data from the HARMONi-2 Study At the 2026 European Lung Cancer Congress
31/03	Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
27/03	Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026
27/03	Akeso Widens Loss in 2025; Shares Climb 3%
27/03	Akeso Reports Full-Year 2025 Financial Results